Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018
- PMID: 30739795
- DOI: 10.1016/j.vaccine.2019.01.052
Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018
Abstract
Background: Trivalent adjuvanted influenza vaccine (aIIV3; Fluad®) was approved in the United States (U.S.) in 2015 for adults aged ≥65 years and has been in use since the 2016-17 influenza season.
Methods: We analyzed U.S. reports for aIIV3 submitted from July 1, 2016 through June 30, 2018 to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system. Medical records were reviewed for serious reports. Among individuals ≥65 years of age, the relative frequency of the most commonly reported adverse events (AEs) after aIIV3 were compared with non-adjuvanted inactivated influenza vaccines given to adults aged ≥65 years, high-dose trivalent influenza vaccine (IIV3-HD) and trivalent or quadrivalent vaccines (IIV3/IIV4). Data mining analyses were undertaken to identify whether AEs for aIIV3 occurred disproportionately more than expected compared to all influenza vaccines.
Results: VAERS received 630 reports after aIIV3, of which 521 (83%) were in adults aged ≥65 years; 79 (13%) in persons <65 years and in 30 (5%) reports age was missing; 19 (3%) reports were serious, including two deaths (0.4%) related to myocardial infarction and Sjogren's syndrome. The most common AEs reported in adults aged ≥65 years were injection site pain (21%) and erythema (18%), with similar proportions reported for IIV3-HD (17% and 19%, respectively) and for IIV3/IIV4 (15%, each). Except for reports related to vaccination of inappropriate age (n = 79) and syringe malfunction (n = 6), data mining did not identify other disproportionately reported AEs.
Conclusions: Although our review of aIIV3 in VAERS did not identify any unexpected health conditions of concern, we observed more than twice the expected number of reports with administration of the vaccine to persons outside of the age range for which the vaccine is approved in the U.S. Health care providers should be educated on the age groups for whom aIIV3 is recommended.
Keywords: Adjuvanted influenza vaccine MF59® (Fluad); Attenuated influenza vaccine; Post-licensure surveillance; Vaccine adverse event reporting system; Vaccine safety.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Vaccine. 2016. PMID: 27015735 Free PMC article. Review.
-
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.Vaccine. 2020 Aug 18;38(37):5923-5926. doi: 10.1016/j.vaccine.2020.07.007. Epub 2020 Jul 21. Vaccine. 2020. PMID: 32709434 Review.
-
Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22. Vaccine. 2014. PMID: 25258101
-
Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.Clin Infect Dis. 2021 Sep 7;73(5):816-823. doi: 10.1093/cid/ciab152. Clin Infect Dis. 2021. PMID: 33605977 Free PMC article.
-
MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.Int J Infect Dis. 2019 Aug;85S:S18-S25. doi: 10.1016/j.ijid.2019.04.023. Epub 2019 Apr 30. Int J Infect Dis. 2019. PMID: 31051279
Cited by
-
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0].J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec. J Prev Med Hyg. 2023. PMID: 37034835 Free PMC article. Italian. No abstract available.
-
Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season.Hum Vaccin Immunother. 2023 Dec 31;19(1):2190279. doi: 10.1080/21645515.2023.2190279. Epub 2023 Mar 15. Hum Vaccin Immunother. 2023. PMID: 36919537 Free PMC article.
-
Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice.Sci Rep. 2023 Jan 13;13(1):715. doi: 10.1038/s41598-023-27965-x. Sci Rep. 2023. PMID: 36639569 Free PMC article.
-
OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines.Heliyon. 2022 Nov 11;8(11):e11515. doi: 10.1016/j.heliyon.2022.e11515. eCollection 2022 Nov. Heliyon. 2022. PMID: 36411908 Free PMC article.
-
"World in motion" - emulsion adjuvants rising to meet the pandemic challenges.NPJ Vaccines. 2021 Dec 21;6(1):158. doi: 10.1038/s41541-021-00418-0. NPJ Vaccines. 2021. PMID: 34934069 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical